Therapeutic role of <i>Azadirachta indica</i> leaves ethanolic extract against diabetic nephropathy in rats neonatally induced by streptozotocin

El-Beltagy, Abd El-Fattah B. M.; Saleh, Amira M. B.; Attaallah, Amany; Gahnem, Reham A.

doi:10.1080/01913123.2021.1988015

Cited by 6 publications

(2 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some cases, if the disorder is recognized early in the course of the disease, neurodegenerative disability may be limited. Effective and timely treatment may inhibit both the progression of DM and diseases of the nervous system, such as cognitive loss [26,28,33,52,69,70,84,94,104,120,127,[131][132][133][134][135][136][137][138][139]. Although the use of current pharmaceuticals and diet modification can assist in the treatment of DM and metabolic disorders to prevent hyperglycemic events, these strategies have potential risks that can decrease organ mass, affect cellular organelles, and lead to neuronal loss through processes that involve autophagy [104,124,140,141].…”

Section: New Treatment Strategies To Address Cellular Metabolism Dysf...mentioning

confidence: 99%

Cellular Metabolism: A Fundamental Component of Degeneration in the Nervous System

Maiese

2023

Biomolecules

View full text Add to dashboard Cite

It is estimated that, at minimum, 500 million individuals suffer from cellular metabolic dysfunction, such as diabetes mellitus (DM), throughout the world. Even more concerning is the knowledge that metabolic disease is intimately tied to neurodegenerative disorders, affecting both the central and peripheral nervous systems as well as leading to dementia, the seventh leading cause of death. New and innovative therapeutic strategies that address cellular metabolism, apoptosis, autophagy, and pyroptosis, the mechanistic target of rapamycin (mTOR), AMP activated protein kinase (AMPK), growth factor signaling with erythropoietin (EPO), and risk factors such as the apolipoprotein E (APOE-ε4) gene and coronavirus disease 2019 (COVID-19) can offer valuable insights for the clinical care and treatment of neurodegenerative disorders impacted by cellular metabolic disease. Critical insight into and modulation of these complex pathways are required since mTOR signaling pathways, such as AMPK activation, can improve memory retention in Alzheimer’s disease (AD) and DM, promote healthy aging, facilitate clearance of β-amyloid (Aß) and tau in the brain, and control inflammation, but also may lead to cognitive loss and long-COVID syndrome through mechanisms that can include oxidative stress, mitochondrial dysfunction, cytokine release, and APOE-ε4 if pathways such as autophagy and other mechanisms of programmed cell death are left unchecked.

show abstract

Section: New Treatment Strategies To Address Cellular Metabolism Dysf...mentioning

confidence: 99%

Cellular Metabolism: A Fundamental Component of Degeneration in the Nervous System

Maiese

2023

Biomolecules

View full text Add to dashboard Cite

show abstract

“…Apoptosis during DM can lead to atherosclerotic plaque generation [296,301,302], foster processes associated with infection, such as COVID-19 [59,71,303,304], promote joint degenerative diseases [152,293,[305][306][307], and enhance stem cell demise and inflammatory pathway activation [26,103,129,132,291,[308][309][310][311][312][313][314]. Apoptosis during metabolic disorders also can be involved in adipose tissue inflammation during loss of metabolic homeostasis [315], may lead to cognitive loss in combination with autophagic pathways [77], promote microglial activation to the detriment of cells [26], impair pancreatic β-cell function [61,316], promote demyelination of nerve fibers [317], lead to ischemic cell injury [63], result in retinal cell loss [75,76,292,[318][319][320][321], foster renal cell injury [43,220,322], and lead to vascular cell degeneration [53, 101,215,…”

Section: Cellular Mechanisms Of Oxidative Stress Energy Metabolism An...mentioning

confidence: 99%

Cornerstone Cellular Pathways for Metabolic Disorders and Diabetes Mellitus: Non-Coding RNAs, Wnt Signaling, and AMPK

Maiese

2023

Cells

View full text Add to dashboard Cite

Metabolic disorders and diabetes (DM) impact more than five hundred million individuals throughout the world and are insidious in onset, chronic in nature, and yield significant disability and death. Current therapies that address nutritional status, weight management, and pharmacological options may delay disability but cannot alter disease course or functional organ loss, such as dementia and degeneration of systemic bodily functions. Underlying these challenges are the onset of aging disorders associated with increased lifespan, telomere dysfunction, and oxidative stress generation that lead to multi-system dysfunction. These significant hurdles point to the urgent need to address underlying disease mechanisms with innovative applications. New treatment strategies involve non-coding RNA pathways with microRNAs (miRNAs) and circular ribonucleic acids (circRNAs), Wnt signaling, and Wnt1 inducible signaling pathway protein 1 (WISP1) that are dependent upon programmed cell death pathways, cellular metabolic pathways with AMP-activated protein kinase (AMPK) and nicotinamide, and growth factor applications. Non-coding RNAs, Wnt signaling, and AMPK are cornerstone mechanisms for overseeing complex metabolic pathways that offer innovative treatment avenues for metabolic disease and DM but will necessitate continued appreciation of the ability of each of these cellular mechanisms to independently and in unison influence clinical outcome.

show abstract

The Metabolic Basis for Nervous System Dysfunction in Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease

Maiese

2023

CNR

View full text Add to dashboard Cite

Disorders of metabolism affect multiple systems throughout the body but may have the greatest impact on both central and peripheral nervous systems. Currently available treatments and behavior changes for disorders that include diabetes mellitus (DM) and nervous system diseases are limited and cannot reverse the disease burden. Greater access to healthcare and a longer lifespan have led to an increased prevalence of metabolic and neurodegenerative disorders. In light of these challenges, innovative studies into the underlying disease pathways offer new treatment perspectives for Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease. Metabolic disorders are intimately tied to neurodegenerative diseases and can lead to debilitating outcomes, such as multi-nervous system disease, susceptibility to viral pathogens, and long-term cognitive disability. Novel strategies that can robustly address metabolic disease and neurodegenerative disorders involve a careful consideration of cellular metabolism, programmed cell death pathways, the mechanistic target of rapamycin (mTOR) and its associated pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), AMP-activated protein kinase (AMPK), growth factor signaling, and underlying risk factors such as the apolipoprotein E (APOE-4) gene. Yet, these complex pathways necessitate comprehensive understanding to achieve clinical outcomes that target disease susceptibility, onset, and progression.

show abstract

Therapeutic role of Azadirachta indica leaves ethanolic extract against diabetic nephropathy in rats neonatally induced by streptozotocin

Cited by 6 publications

References 63 publications

Cellular Metabolism: A Fundamental Component of Degeneration in the Nervous System

Cellular Metabolism: A Fundamental Component of Degeneration in the Nervous System

Cornerstone Cellular Pathways for Metabolic Disorders and Diabetes Mellitus: Non-Coding RNAs, Wnt Signaling, and AMPK

The Metabolic Basis for Nervous System Dysfunction in Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease

Contact Info

Product

Resources

About